Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest G protein-coupled receptor Stories

2014-03-27 08:34:12

Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi's iCAPS platform LA JOLLA, Calif. and SHANGHAI, March 27, 2014 /PRNewswire/ -- RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of...

2014-03-26 04:21:13

LONDON and BOSTON, March 26, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that a company presentation to be given by its Chief Executive Officer, Malcolm Weir, at BioCentury Future Leaders in the Biotech Industry [https://www.biocentury.com/conferences/futureleaders/dates ] on 28 March 2014 will be webcast live. The presentation will take place at 9.30am ET in room 302/303 at the Millennium Broadway...

Heart Attack Patients May Soon Have Side Effect-Free Drug Option
2014-03-12 06:36:52

April Flowers for redOrbit.com - Your Universe Online A new drug designed to stop a heart attack in its tracks, while reducing the damage caused, all without side effects, is one step closer to development thanks to a group of Melbourne scientists from Monash University. New hope for thousands of people who experience heart attacks and heart failure is provided by the study, published in a recent issue of Proceedings of the National Academy of Sciences. A team of scientists, led by...

2014-03-07 08:25:11

LONDON and BOSTON, March 7, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that its Chief Executive Officer, Malcolm Weir, will participate in a panel discussion entitled, "Addressing cognitive deficits across CNS disorders: Potential to improve overall functional outcomes and QoL" (2:45pm-3:45pm CET on 10 March) at BIO-Europe Spring 2014 [http://www.ebdgroup.com/bes/index.php ], which takes place in...

2014-01-23 04:21:26

LONDON and BOSTON, January 23, 2014 /PRNewswire/ -- Stabilised GPCR (StaR(R)) Proteins Delivered For All Nominated Targets Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, has successfully completed the research phase of its antibody drug discovery collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. In achieving this milestone, Heptares has delivered StaR(R) proteins...

Scientists Solve Mystery Of How Sodium Controls Opioid Brain Signaling
2014-01-13 07:13:26

Scripps Research Institute The findings pave way for new therapies for treating pain and mood disorders Scientists have discovered how the element sodium influences the signaling of a major class of brain cell receptors, known as opioid receptors. The discovery, from The Scripps Research Institute (TSRI) and the University of North Carolina (UNC), suggests new therapeutic approaches to a host of brain-related medical conditions. "It opens the door to understanding opioid related...

2014-01-09 04:20:56

LONDON and BOSTON, January 9, 2014 /PRNewswire/ -- Increases Focus on Clinical Development of Novel GPCR-targeted Drug Candidates Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces the appointment of Dr Tim Tasker as Chief Medical Officer (CMO) and Vice President of Development. Dr Tasker will lead the Company's clinical development activities as it advances its...

2014-01-08 04:21:15

WELWYN GARDEN CITY, England and BOSTON, January 8, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that its President, Dan Grau, will moderate a panel discussion entitled "Global Entrepreneurs: Biotech Building Beyond Borders" (1:30-2:00pm Eastern time on 11 January) at the Boston Biotech East/West CEO Conference [http://bbbiotechconference.com/conference-agenda.php?id=14 ], which takes place at the Four Seasons...

Xray Maps GPCR
2013-12-20 12:57:28

redOrbit Staff & Wire Reports - Your Universe Online Researchers have used one of the brightest X-ray sources in the world to map the three-dimensional structure of an important cellular gatekeeper known as a G protein-coupled receptor, or GPCR, in a more natural state than has been previously possible. The new technique, described Friday in the journal Science, is a major leap forward in exploring GPCRs, a vast, hard-to-study family of proteins that plays a key role in human health...

2013-12-18 08:28:28

STRASBOURG AND MONTRÉAL, Dec. 18, 2013 /PRNewswire/ - Domain Therapeutics, a France-based biopharmaceutical company that specializes in the research and development of new drug candidates that target G-protein coupled receptors (GPCRs), is pleased to announce the signing of a licensing and partnership agreement on GPCR biosensor technology with Université de Montréal (UdeM) and its commercialization unit, with the Institute for Research in Immunology and Cancer -...